-
Nature and Science of Sleep
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Clinical evaluation of zaleplon in the treatment of insomnia
Review
(2648) Views (663) Full article downloads
Authors: Marieke M Ebbens, Joris C Verster
Published Date July 2010
Volume 2010:2 Pages 115 - 126
DOI: http://dx.doi.org/10.2147/NSS.S6853
Marieke M Ebbens, Joris C VersterUtrecht Institute for Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, The Netherlands
Abstract: Zaleplon is a pyrazolopyrimidine hypnotic used for the treatment of insomnia. Zaleplon binds preferentially at the a1ß2γ2 subunit of gamma aminobutyric acid type A (GABAA) receptors in the central nervous system, and has a half-life of about one hour. Efficacy studies show that zaleplon is a suitable hypnotic for sleep initiation purposes. However, because of its short half-life, zaleplon is less effective in sleep maintenance when compared with other hypnotics. Nevertheless, zaleplon does increase total sleep time. No rebound effects are observed after treatment discontinuation. The use of zaleplon is relatively safe. Adverse effects are mild and of short duration. No important interactions have been reported, and there is no evidence of abuse potential. Relative to benzodiazepine hypnotics, the biggest advantage of zaleplon is that current evidence suggests it does not produce residual next-day effects. As early as four hours after intake of zaleplon, no effects on cognitive, memory, psychomotor performance, and the ability to drive a car have been reported. Future studies should confirm these findings, and comparisons with new nonbenzodiazepine hypnotics should determine the importance of zaleplon in the future treatment of insomnia.
Keywords: zaleplon, zolpidem, hypnotics, efficacy, safety, residual effects
Other articles by Dr Joris Verster
Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP)
The RT-18: a new screening tool to assess young adult risk-taking behavior
Readers of this article also read:
Tackling sleeplessness: Psychological treatment options for insomnia
Management of insomnia: update and new approaches
Role of 5-HT2A receptor antagonists in the treatment of insomnia
Update on the management of restless legs syndrome: existing and emerging treatment options
Critical appraisal of ramelteon in the treatment of insomnia
Pharmacotherapy for treatment-resistant schizophrenia
Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP)
The RT-18: a new screening tool to assess young adult risk-taking behavior
Energy drinks mixed with alcohol: misconceptions, myths, and facts
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
- Implementing the 2009 Institute of Medicine recommendations on resident physician work hours, supervision, and safety
- Moderate alcohol consumption and cognitive risk
- Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference




